Phase II/III trial of sustained-release fampridine for the treatment of post-stroke walking deficits
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III
Latest Information Update: 22 Nov 2016
Price : $35 *
At a glance
- Drugs Fampridine (Primary)
- Indications Stroke complications
- Focus Therapeutic Use
- Sponsors Acorda Therapeutics
- 22 Nov 2016 According to an Acorda Therapeutics media release, the company has decided to discontinue further development of dalfampridine for the treatment of post-stroke walking difficulties based on results of MILESTONE trial.
- 22 Nov 2016 According to an Acorda Therapeutics media release, status changed from planning to withdrawn prior to enrolment.
- 01 Aug 2013 New trial record